150 related articles for article (PubMed ID: 31931437)
1. Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies.
Rashid M; Rajan AK; Chhabra M; Kashyap A
Seizure; 2020 Feb; 75():101-109. PubMed ID: 31931437
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate related cutaneous adverse drug reactions: a systematic literature review.
Zuber M; Harikrishna ; Vidhyashree ; Chhabra M; Venkataraman R; Kumar S; Rashid M
J Basic Clin Physiol Pharmacol; 2022 Sep; 33(5):549-565. PubMed ID: 34706401
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam-induced cutaneous adverse drug reactions were not associated with HLA genes in a small sample of Chinese patients with epilepsy.
Hu FY; Wang W; Ren JC; An DM; Chen JN; Zhou D
Epilepsy Res; 2016 Aug; 124():12-5. PubMed ID: 27162008
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin-induced cutaneous adverse drug events: a systematic review of descriptive studies.
Kashyap A; Sreenivasan S; Rajan AK; Rashid M; Chhabra M
J Basic Clin Physiol Pharmacol; 2021 Mar; 33(3):327-346. PubMed ID: 33725760
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions and organ damage: The skin.
Marzano AV; Borghi A; Cugno M
Eur J Intern Med; 2016 Mar; 28():17-24. PubMed ID: 26674736
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of Cutaneous Adverse Reactions to Levetiracetam and Human Leukocyte Antigen Typing in North-Indian Patients.
Ramanujam B; Ihtisham K; Kaur G; Srivastava S; Mehra NK; Khanna N; Singh M; Tripathi M
J Epilepsy Res; 2016 Dec; 6(2):87-92. PubMed ID: 28101480
[TBL] [Abstract][Full Text] [Related]
7. Metronidazole Induced Cutaneous Adverse Drug Reaction- A Systematic Review of Descriptive Studies.
Taj S; Zuber M; Hanumanthaiah VB; Venkataraman R; Puttegowda SK; Afrid S; Kiran S
Curr Rev Clin Exp Pharmacol; 2024; 19(3):269-284. PubMed ID: 37264661
[TBL] [Abstract][Full Text] [Related]
8. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance.
Turk BG; Gunaydin A; Ertam I; Ozturk G
Cutan Ocul Toxicol; 2013 Mar; 32(1):41-5. PubMed ID: 22812902
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies.
Rashid M; Kashyap A; Undela K
Int J Dermatol; 2019 Sep; 58(9):1014-1022. PubMed ID: 30809807
[TBL] [Abstract][Full Text] [Related]
10. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
11. The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy.
Gulcebi MI; Kendirli T; Turgan ZA; Patsalos PN; Onat Yilmaz F
Epilepsy Res; 2018 Dec; 148():17-22. PubMed ID: 30326332
[TBL] [Abstract][Full Text] [Related]
12. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events.
Jalihal V; Shankar R; Henley W; Parrett M; Tittensor P; McLean BN; Ahmed A; Sander JW
Epilepsy Behav; 2018 Mar; 80():365-369. PubMed ID: 29415871
[TBL] [Abstract][Full Text] [Related]
13. Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population.
Ihtisham K; Ramanujam B; Srivastava S; Mehra NK; Kaur G; Khanna N; Jain S; Kumar S; Kaul B; Samudrala R; Tripathi M
Seizure; 2019 Mar; 66():99-103. PubMed ID: 30826555
[TBL] [Abstract][Full Text] [Related]
14. Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review.
Romoli M; Perucca E; Sen A
Epilepsy Behav; 2020 Feb; 103(Pt A):106861. PubMed ID: 31917143
[TBL] [Abstract][Full Text] [Related]
15. Incidence of cutaneous adverse drug reactions among medical inpatients of Sultanah Aminah Hospital Johor Bahru.
Latha S; Choon SE
Med J Malaysia; 2017 Jun; 72(3):151-156. PubMed ID: 28733562
[TBL] [Abstract][Full Text] [Related]
16. A Rare Case of Levetiracetam and Drug-Induced Idiopathic Aseptic Meningitis in a Pediatric Patient.
McDonald D; Sultan R; Viswanathan A; Siu A
Pharmacotherapy; 2019 Jan; 39(1):109-113. PubMed ID: 30488976
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam-Associated Psychogenic Non-epileptic Seizures; A Hidden Paradox.
Jabeen SA; Gaddamanugu P; Cherian A; Mridula KM; Kumar DU; Meena AK
J Popul Ther Clin Pharmacol; 2018 Jul; 25(2):e1-e11. PubMed ID: 30725538
[TBL] [Abstract][Full Text] [Related]
18. Risk factors predisposing to psychotic symptoms during levetiracetam therapy: A retrospective study.
Pinckaers FME; Boon ME; Majoie MHJM
Epilepsy Behav; 2019 Nov; 100(Pt A):106344. PubMed ID: 31525554
[TBL] [Abstract][Full Text] [Related]
19. Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population.
Mushiroda T; Takahashi Y; Onuma T; Yamamoto Y; Kamei T; Hoshida T; Takeuchi K; Otsuka K; Okazaki M; Watanabe M; Kanemoto K; Oshima T; Watanabe A; Minami S; Saito K; Tanii H; Shimo Y; Hara M; Saitoh S; Kinoshita T; Kato M; Yamada N; Akamatsu N; Fukuchi T; Ishida S; Yasumoto S; Takahashi A; Ozeki T; Furuta T; Saito Y; Izumida N; Kano Y; Shiohara T; Kubo M;
JAMA Neurol; 2018 Jul; 75(7):842-849. PubMed ID: 29610831
[TBL] [Abstract][Full Text] [Related]
20. A Study of Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Andhra Pradesh, India.
Ashifha S; Vijayashree J; Vudayana K; Chintada D; P P; G P; Unnikrishnan P
Cureus; 2023 Apr; 15(4):e37596. PubMed ID: 37197134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
